Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors

@article{Reidy2009TreatmentOA,
  title={Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors},
  author={Diane L. Reidy and Laura H. Tang and Leonard B. Saltz},
  journal={Nature Clinical Practice Oncology},
  year={2009},
  volume={6},
  pages={143-152},
  url={https://api.semanticscholar.org/CorpusID:25462610}
}
Advances in the understanding of tumor biology have led to the identification of important cellular processes involved in the pathogenesis of NETs, and agents that target these processes have now entered clinical trials.
View on Nature
ncbi.nlm.nih.gov
30 Citations
Highly Influential Citations
2
Background Citations
14
Results Citations
1

30 Citations

Emerging therapies for pancreas neuroendocrine cancers.

The next generation of studies in PNET will help define optimal sequencing strategies of available therapies and also will attempt to use biomarker-guided approaches to select therapies.

Progress in the treatment of esophageal neuroendocrine carcinoma

Surgical treatment is key to treating esophageal neuroendocrine neoplasms, but combined treatment with chemotherapy and radiotherapy can significantly improve patient survival, and the effect of radiotherapy alone on this disease is poor.

Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.

This review will present the most widely used systems for classifying, grading, and staging NETs and will summarize the recommendations for the data to be included in standard pathology reports of these uncommon tumors.

Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors (PNETs) are becoming increasingly common, with the majority of patients presenting with either lymph node involvement or metastatic disease, thus requiring systemic…

T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

A robust T cell infiltrate is associated with improved RFS following resection of intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment of NETLMs.

Classification of Neuroendocrine Tumors: Consensus Guidelines for the Management and Treatment

This review examines issues in the pathologic assessment of NETs that are common among primaries of different sites and compares various systems of nomenclature, such as the distinction of well-differentiated from poorly differentiated, and the significance of proliferative rate in prognostic assessment.

Metastatic insulinoma: current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs.

This case report follows the clinical course and management of a patient with an insulin-secreting metastatic panNET who died 10 years after diagnosis after a treatment course with regional therapy and multiple forms of cytotoxic and molecularly targeted agents.

Consensus guidelines for the management and treatment of neuroendocrine tumors.

A set of consensus tables intended to complement the North American Neuroendocrine Tumor Society guidelines and serve as a quick, accessible reference for the practicing physician are presented.

Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

The most recent available data on medical therapy for GEPNETs is summarized, finding the relevance of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway seems to be crucial in gastroenteropancreatic (GEP)-NETs.

Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor Entities.

Treatment of SCOCPT should be based on the therapies used to treat other small cell carcinomas, and surgery is appropriate, especially in very early stages of disease, but chemotherapy should not be omitted.

88 References

Prognostic Factors in Gastrointestinal Endocrine Tumors

A recent proposal of tumor grading and tumor, nodes, and metastases (TNM) staging aims at a simple and practical system for patients stratification and should be implemented in routine clinical practice.

Hepatic neuroendocrine metastases: does intervention alter outcomes?

The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas

Systemic therapy for carcinoid tumors and islet cell carcinomas should be carried out in a research setting to restore the patient to a better general and nutritional status so that more aggressive and definitive therapy can be undertaken with an acceptable risk.

Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience

Organ-preserving resections offer sufficient local control in LGC; therefore, radical resection does not seem to be justified and is indicated even in metastasized patients or in case of loco-regional recurrence.

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.

On the basis of the less favorable response of neuroendocrine foregut tumors to biotherapy, chemotherapy should be initiated after failure of biotherapy in documented tumor progression, and chemotherapy of liver metastases should follow biotherapy.

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS, and the volume of metastases in the liver is the most important predictor of outcome.

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

The anaplastic neuroendocrine tumor is strongly responsive to therapy with combined etoposide and cisplatin and should be evaluated for this possibility with appropriate immune staining or electron microscopy.

Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?

It is suggested that aggressive management of neuroendocrine hepatic metastases does improve survival, that chemoembolization increases the patient population eligible for this strategy, and that patients with more than 50% liver involvement may not benefit from an aggressive approach.

Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Accurate prognostic information can be obtained by combining tumor size and metastases with simple grading information based on necrosis and mitotic rate.
...